Potential of Vitex negundo roots in the treatment of ulcerative colitis in mice

Pharmaceutical Biology

Volumn 49, Issue 8, 2011, Pages 874-878

  Zaware, Bharati B ^a   Nirmal, Sunil A ^a   Baheti, D G ^b   Patil, Anuja N ^a   Mandal, Subhash C ^c  

^a PRAVARA RURAL COLLEGE OF PHARMACY   (India)

^b Affiliated to Savitribai Phule Pune University   (India)

^c JADAVPUR UNIVERSITY   (India)

Author keywords

histopathology; malondialdehyde activity; Myeloperoxidase

Indexed keywords

ALCOHOL; MALONALDEHYDE; MYELOPEROXIDASE; PREDNISOLONE; VITEX NEGUNDO EXTRACT; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; COLON; CONTROLLED STUDY; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PLANT ROOT; ULCERATIVE COLITIS; VALIDATION STUDY; VITEX; VITEX NEGUNDO;

ANIMALS; COLITIS, ULCERATIVE; COLON; DOSE-RESPONSE RELATIONSHIP, DRUG; INDIA; MALE; MALONDIALDEHYDE; MICE; PEROXIDASE; PHYTOTHERAPY; PLANT EXTRACTS; PLANT ROOTS; PREDNISOLONE; PROTECTIVE AGENTS; VITEX;

MUS; VERBENACEAE; VITEX NEGUNDO;

EID: 79959616637     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2010.551778     Document Type: Article

References (22)

1. Akgun E, Caliskan C, Celik HA, Ozutemiz AO, Tuncyurek M, Aydin HH. (2005). Effects of N-acetylcysteine treatment on oxidative stress in acetic acid-induced experimental colitis in rats. J Int Med Res, 33, 196-206. (Pubitemid 40372435)
2. Ardizzone S, Bianchi Porro G. (2005). Biologic therapy for inflammatory bowel disease. Drugs, 65, 2253-2286. (Pubitemid 41571985)
3. Buege JA, Aust SD. (1978). Microsomal lipid peroxidation. Meth Enzymol, 52, 302-310.
4. Cetinkaya A, Bulbuloglu E, Kurutas EB, Ciralik H, Kantarceken B, Buyukbese MA. (2005). Beneficial effects of N-acetylcysteine on acetic acid-induced colitis in rats. Tohoku J Exp Med, 206, 131-139. (Pubitemid 40895042)
5. Church DF, Pryor WA. (1985). Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect, 64, 111-126. (Pubitemid 16135783)
6. Evans M, Laszlo R, Brendan J, Whitlle R. (2000). Site specific lesion formation inflammation and inducible nitric oxide synthase expression by indomethacin in the rat intestine. Eur J Pharm, 388, 281-285.
7. Goel RK, Sairam K. (2002). Antiulcer drugs from indigenous sources with emphasis on Musasapientum tamrabhasma, Asparagus racemosus and Zingiber officinale. Indian J Pharmacol, 34, 100-110. (Pubitemid 34308518)
8. Grzanna R, Lindmark L, Frondoza CG. (2005). Ginger-an herbal medicinal product with broad anti-inflammatory actions. J Med Food, 8, 125-132. (Pubitemid 41008974)
9. Kirtikar KR, Basu BD. (1956). Indian Medicinal Plants, second edition. Deharadun, Uttarakhand, India: International Book Distributors, 723.
10. Krawisz JE, Sharon P, Stenson WF. (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology, 87, 1344-1350. (Pubitemid 15201434)
11. Kruidenier L, Kuiper I, Lamers CB, Verspaget HW. (2003). Intestinal oxidative damage in inflammatory bowel disease: Semiquantification, localization, and association with mucosal antioxidants. J Pathol, 201, 28-36. (Pubitemid 37121200)
12. Mahgoub AA, El-Medany AA, Hager HH, Mustafa AA, El-Sabah DM. (2003). Evaluating the prophylactic potential of zafirlukast against the toxic effects of acetic acid on the rat colon. Toxicol Lett, 145, 79-87. (Pubitemid 38366131)
13. Mohan H. (2005). Textbook of Pathology, fifth edition. New Delhi, India: Jaypee Brothers Medical Publishers, 580.
14. Nadkarni AK. (1991). Indian Materia Medica, third edition. Bombay, Maharashtra, India: Bombay Popular Prakashan, 1197-1198.
15. Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. (2006). Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol, 12, 4628-4635. (Pubitemid 44269718)
16. Nakhai LA, Nakhai LA, Yasa N, Boushe VS. (2007). Benefits of Zataria multiflora Boiss in experimental model of mouse inflammatory bowel disease. Evid Based Complement Alternat Med, 4, 43-50. (Pubitemid 46410877)
17. Otani T, Yamaguchi K, Scherl E, Du B, Tai H, Greifer M, Petrovic L, Daikoku T, Dey SK, Subbaramaiah K, Dannenberg AJ. (2006). Levels of NAD+-dependent 15 hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: Evidence for involvement of TNF-α. Am J Physiol Gastrointest Liver Physiol, 290, G361-G368.
18. Rutgeerts P, Geboes K. (2001). Understanding inflammatory bowel disease-the clinician's perspective. Eur J Surg Suppl, 586, 66-72. (Pubitemid 32977807)
19. Sands BE, Kaplan GG. (2007). The role of TNFalpha in ulcerative colitis. J Clin Pharmacol, 47, 930-941.
20. Sartor RB. (1997). Pathogenesis and immune mechanisms of chronic inflammatory bowel disease. Am J Gastroenterol, 92, 5S-11S.
21. Stucchi A, Reed K, O'Brien M, Cerda S, Andrews C, Gower A, Bushell K, Amar S, Leeman S, Becker J. (2006). A new transcription factor that regulates TNFalpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC. Inflammatory Bowel Disease, 12, 581-587. (Pubitemid 43977739)
22. Wiercinska-Drapalo A, Flisiak R, Prokopowicz D. (1999). Mucosal and plasma prostaglandin E2 in ulcerative colitis. Hepatogastroenterology, 46, 2338-2342. (Pubitemid 29454095)